Tofacitinib inhibits granulocyte–macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils
Makiko Yashiro Furuya(Fukushima Medical University), Kiyoshi Migita(Fukushima Medical University), Shuzo Sato(Fukushima Medical University), Tomohiro Koga(Beth Israel Deaconess Medical Center), Hideko Kozuru(Nagasaki Medical Center), Yuya Sumichika(Fukushima Medical University), Hiromasa Ohira(Fukushima Medical University), Hiroshi Yatsuhashi(Nagasaki Medical Center), Tomoyuki Asano(Fukushima Medical University), Atsushi Kawakami(Nagasaki University), Hiroshi Watanabe, Eiji Suzuki(Ohta Nishinouchi Hospital), Hiroko Kobayashi(Fukushima Medical University), Hideharu Sekine(Fukushima Medical University)
Cited by 57
Related Papers
Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis
|Hepatology|2006|365
The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM
|Lara D. Veeken|2012|321
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy
|Annals of the Rheumatic Diseases|2012|266
A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update
|Journal of Gastroenterology|2018|242